Control in $INCY Frontmind (1st-line DLBCL) is R-Chop, not Revlimid + R-Chop. So how do we know the (modest) PFS benefit toplined today is due to $INCY Monjuvi, and not to Revlimid? https://t.co/Swc41ElHFr
Convinced, @PDRennert? INCA33890 #ESMO25 slide via Elena Garralda $INCY https://t.co/jLzyGI8i5w
$INCY only just reported first-in-human data with INCA33890 at #ESMO25. Now the project is starting phase 3! https://t.co/1Muy8jaEPW It's an anti-PD-1 x TGFꞵR2, cc: @PDRennert
Incyte $INCY study results suggest a new approach to treating myelofibrosis. The biotech is hunting for new medicines to help replace its blockbuster Jakafi https://t.co/THEuylLmQq #ASH25
What to expect at the #ASH25 meeting, and some thoughts on the FDA’s Richard Pazdur https://t.co/2Upwf0Oh9M $TERN $INCY $ACLX $FULC
If you need some biotech reading over Thanksgiving check out @ApexOnco previews of #ASH25 --> https://t.co/cqsR1AVbPH Starts in just over a week! $ACLX $ONC $CRVS $TERN $KURA $SNDX $CGEM $INCY
Paragon Therapeutics spinning out another company, Damora Therapeutics, focused on mutCALR - a buzzy target for myelofibrosis and related diseases. $INCY has one, with data coming at ASH. Damora coming public via merger with $GLTO + $285M PIPE. https://t.co/Ma0nR4TXiT
@AppleHelix Just an option. I was amazed $INCY allowed $PRLD to reveal the up-front amounts, but I guess it had to since it's clearly material for the latter.
This is amazing. $INCY just handed across $60m for a preclinical asset to which it hasn't even secured rights (yet). $PRLD $COGT
Who won #ESMO25 and who lost? Via @ApexOnco https://t.co/EWzHIIH1Ck $IOBT $CELC $RCUS $CGEM $IDYA $NUVL $AGEN $GILD $DSNKY $INCY $CATX $LPTX $OLMA $SMMT $AVBP $GMAB $EXEL $CGEN $ZLAB $RHHBY
Good morning biotwitter! If you're catching up with #ESMO25 here's what we've published over the weekend https://t.co/lzhy6k4Raz Stocks to watch this morning: $GMAB $CELC $IOBT $MRUS $INCY $RCUS $AVBP $SMMT $NUVL $IMTX $OLMA $CGEM
#ESMO25 regular abstracts are now live, with first-in-human data being revealed by $LLY $INCY $DSNKY $MRNA $NVS Parabilis & others. Preview via @ApexOnco https://t.co/4oZFL7a5bt
A new CDK2 degrader, plus $KYMR's return to oncology. Via @ApexOnco -> https://t.co/9iW8otUzvn $GILD $PFE $INCY $RHHBY $GLUE $BPMC
$INCY reckons CALR holds the key to treating the root cause of essential thrombocythemia, but does that imply a vanishingly small market? @ApexOnco from #EHA25 -> https://t.co/bIcGps74sr $MRK
